DMT, the spirit molecule, protects brain from stroke in mice, study finds

A team of Hungarian researchers reports that a molecule best known for producing powerful psychedelic experiences may also protect brain tissue after a stroke. In laboratory tests on animals and isolated cells, the compound—N,N-dimethyltryptamine, or DMT—appeared to repair critical vascular structures and tamp down damaging inflammation, offering a fresh angle on a condition with few effective treatments.

The experiments, carried out by scientists in Szeged and Budapest and published in Science Advances, do not mean DMT is ready for clinical use. Still, the results open the door to novel therapies that target both the brain’s vascular barrier and the immune response that amplifies stroke damage.

New laboratory evidence: DMT shields the blood-brain barrier after stroke

Researchers led by Mária Deli, Zoltán Nagy and Sándor Nardai exposed mice and cultured brain cells to DMT following induced ischemic injury. The most striking finding was recovery of the blood-brain barrier’s structure and function—an essential safeguard that normally keeps toxins and peripheral immune cells out of sensitive brain tissue.

DMT treatment reduced lesion size and swelling (edema) in the animals, while improving the performance of astrocytes, the star-shaped support cells that help maintain the barrier and support neurons. The compound also curbed production of inflammatory signaling molecules from both brain endothelial cells and circulating immune cells, a dual action that investigators say could be clinically useful.

Key experimental outcomes

• Reconstruction of disrupted blood-brain barrier architecture in affected brain regions.
• Improved astrocyte function and cellular resilience following ischemia.
• Lower levels of pro-inflammatory cytokines in brain and peripheral immune cells.
• Marked reductions in infarct volume and edema in treated mice.

What DMT is and why it matters biologically

N,N-dimethyltryptamine is a powerful psychoactive indoleamine found in numerous plant species and produced naturally in humans. It has been associated with intense subjective experiences—sometimes described as ego dissolution, encounters with nonordinary entities, or transcendent feelings of connection. Beyond its perceptual effects, DMT interacts with several receptor systems and cellular pathways that may influence inflammation, neuroprotection, and vascular integrity.

Because DMT is both endogenous and widely present in nature, researchers see potential for therapeutic repurposing, although translating laboratory findings into safe, standardized treatments will require careful work to separate beneficial biochemical effects from psychedelic experiences where necessary.

Clinical development, legal landscape, and research hurdles

Early-stage clinical testing of DMT-based interventions has already begun in some countries, and long-term safety studies are underway. Still, the path from animal studies to routine medical use is long: scientists need to confirm efficacy in humans, optimize dosing and delivery, and address safety issues, including the compound’s psychoactive properties.

Legal frameworks complicate research and potential rollout. Many European nations, Hungary included, classify DMT as a controlled hallucinogen. At the same time, countries such as the Netherlands and Portugal have taken more permissive stances toward DMT-containing traditional preparations like ayahuasca, which can ease study and therapeutic access in some jurisdictions.

Next steps researchers are pursuing

• Rigorous human clinical trials to evaluate safety, tolerability, and efficacy after stroke.
• Pharmacological work to define optimal dosing windows and delivery methods.
• Investigations into whether non-hallucinogenic analogs can preserve protective effects.
• Combination studies testing DMT alongside established stroke treatments (e.g., reperfusion therapies).

Public health implications: stroke burden and why new options are needed

Stroke remains a leading cause of disability and death. In the United States alone, roughly 800,000 strokes occur each year. Recent data show that stroke accounts for about 17.5% (roughly 1 in 6) of cardiovascular deaths, and the economic toll of stroke care and lost productivity reached approximately $56 billion in the referenced reporting year.

Given those numbers, therapies that reduce tissue loss, swelling, and post-stroke inflammation—even if used alongside current interventions—could have significant clinical and economic impact. Researchers say DMT’s combined vascular and immunomodulatory actions make it a compelling candidate for further study, though questions about safety, legality and efficacy in humans remain to be answered.

You might also like:

• Stem cell breakthrough could restore sight for blind people by repairing retinal vessels
• Alzheimer’s antibody from camels and alpacas shows promise as a treatment
• Treatment-resistant breast cancer: antibody breakthrough offers new hope
• Cancer-fighting cells engineered in patients’ bodies for the first time
• MS: high-altitude yak gene protects and repairs myelin in early study

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.